Literature DB >> 8494722

Fluorescence and photodynamic effects of bacteriochlorin a observed in vivo in 'sandwich' observation chambers.

H L van Leengoed1, J J Schuitmaker, N van der Veen, T M Dubbelman, W M Star.   

Abstract

Bacteriochlorin a (BCA), a derivative of bacteriochlorphyll a, is an effective photosensitiser in vitro and in vivo. BCA has a major absorption peak at 760 nm where tissue penetration is optimal. This property, together with rapid tissue clearance promises minor skin photosensitivity. The tissue localising and photodynamic properties of BCA were studied using isogeneic RMA mammary tumours, transplanted into subcutaneous tissue in transparent 'sandwich' observation chambers on the back of WAG/Rij rats. The fluorescence kinetics following an i.v. administration of 20 mg kg-1 BCA was assessed in blood vessels, tumour and normal tissue. Subsequently, the development of vascular- and tissue damage after a therapeutic light dose (760 nm, 600 J cm-2) was observed. Fifteen minutes post injection (p.i.), the fluorescence of BCA in the tumour reached a plateau value of 2.5 times the fluorescence in the normal tissue. From 1 h post injection the tumour fluorescence diminished gradually; after 24 h, the tumour fluorescence signal did not exceed that of the normal tissue. Following photodynamic therapy (PDT), 24 h p.i., complete vascular stasis was observed 2 h post treatment in the tumour only, with subsequent recovery. The presence of viable tumour cells following PDT was assessed by histology and re-transplantation of treated tumour tissue from the chamber into the flank immediately or 7 days after treatment. In both cases tumour regrowth was observed. BCA-PDT (20 mg kg-1, 760 nm, 100 J cm-2) 1 h after BCA administration, an interval which gives the optimal differential between tumour and normal tissue, was sufficient to prevent tumour regrowth. However, this only occurred when re-transplantation was performed 7 days after PDT. During PDT, 1 h p.i., vascular damage in tumour and normal tissue was considerable. Complete vascular shut-down was observed in the tumour 2 h after therapy and in the surrounding tissues at 24 h. Circulation damage was associated with vascular spasm and occlusion probably due to thrombi formation. Oedema was notable, especially following PDT with 600 J cm-2 at 24 h p.i.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494722      PMCID: PMC1968437          DOI: 10.1038/bjc.1993.168

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Reoxygenation of tumours in "sandwich" chambers.

Authors:  H S Reinhold; B Blachiewicz; A Berg-Blok
Journal:  Eur J Cancer       Date:  1979-04       Impact factor: 9.162

Review 2.  How does photodynamic therapy work?

Authors:  B W Henderson; T J Dougherty
Journal:  Photochem Photobiol       Date:  1992-01       Impact factor: 3.421

Review 3.  Preclinical examination of first and second generation photosensitizers used in photodynamic therapy.

Authors:  C J Gomer
Journal:  Photochem Photobiol       Date:  1991-12       Impact factor: 3.421

4.  Bacteriochlorin a, a new photosensitizer in photodynamic therapy. In vivo results.

Authors:  J J Schuitmaker; J A van Best; J L van Delft; T M Dubbelman; J A Oosterhuis; D de Wolff-Rouendaal
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-08       Impact factor: 4.799

5.  Tissue-localizing properties of some photosensitizers studied by in vivo fluorescence imaging.

Authors:  E van Leengoed; J Versteeg; N van der Veen; A van den Berg-Blok; H Marijnissen; W Star
Journal:  J Photochem Photobiol B       Date:  1990-06       Impact factor: 6.252

6.  Detection of early lung cancer using low dose Photofrin II.

Authors:  S Lam; B Palcic; D McLean; J Hung; M Korbelik; A E Profio
Journal:  Chest       Date:  1990-02       Impact factor: 9.410

7.  Morphologic effects of bacteriochlorin a and light in vivo on intraocular melanoma.

Authors:  J J Schuitmaker; G F Vrensen; J L van Delft; D de Wolff-Rouendaal; T M Dubbelman; A de Wolf
Journal:  Invest Ophthalmol Vis Sci       Date:  1991-09       Impact factor: 4.799

8.  Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers.

Authors:  W M Star; H P Marijnissen; A E van den Berg-Blok; J A Versteeg; K A Franken; H S Reinhold
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

9.  The effect of photodynamic therapy on the microcirculation.

Authors:  M W Reed; F N Miller; T J Wieman; M T Tseng; C G Pietsch
Journal:  J Surg Res       Date:  1988-11       Impact factor: 2.192

10.  Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model.

Authors:  A M Richter; E Waterfield; A K Jain; B Allison; E D Sternberg; D Dolphin; J G Levy
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

View more
  4 in total

1.  Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization.

Authors:  Ana P Castano; Tatiana N Demidova; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2004-12       Impact factor: 3.631

2.  Corneal neovascularization in rats as a model for photothrombotic therapy using bacteriochlorin a and an argon laser.

Authors:  C A van Gool; H J Schuitmaker; M J Jager
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-07       Impact factor: 3.117

3.  Interstitial photodynamic therapy with the second-generation photosensitizer bacteriochlorin a in a rat model for liver metastases.

Authors:  J P Rovers; J J Schuitmaker; A L Vahrmeijer; J H van Dierendonck; O T Terpstra
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

4.  Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C.

Authors:  I P van Geel; H Oppelaar; Y G Oussoren; J J Schuitmaker; F A Stewart
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.